Publication: Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Endocrine Society
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Roszko, Kelly Lauter, Erica Blouch, Michael Blake, James F. Powers, Arthur S. Tischler, Richard Hodin, Peter Sadow, and Elizabeth A. Lawson. 2017. “Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas.” Journal of the Endocrine Society 1 (11): 1401-1407. doi:10.1210/js.2017-00135. http://dx.doi.org/10.1210/js.2017-00135.
Research Data
Abstract
Pheochromocytomas are neuroendocrine tumors that can arise sporadically or be inherited as a familial disease, and they may occur in isolation or as part of a multitumor syndrome. Familial disease typically presents in younger patients with a higher risk of multifocality. Recently, the tumor suppressor MYC-associated factor X (MAX) gene has been implicated as a cause of familial isolated pheochromocytoma and paraganglioma. We describe a patient with a pituitary prolactinoma and bilateral pheochromocytomas who tested positive for a germline MAX mutation. Interestingly, the patient also had mild primary hyperparathyroidism that resolved upon resection of the pheochromocytomas despite the absence of parathyroid hormone staining in the tumors. To our knowledge, this case is the first report of prolactinoma in a patient with a MAX mutation, which suggests the possibility of germline MAX mutations also contributing to the development of prolactinomas.
Description
Other Available Sources
Keywords
Pituitary and Neuroendocrinology, MAX mutation, pheochromocytoma, prolactinoma
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service